Our Latest News - BUHLMANN

BUHLMANN News

Visit BUHLMANN at CDDW 2020

Canadian Digestive Diseases Week (CDDW) 2020 BUHLMANN Diagnostics Corp Booth: #13 Feb 28 - Mar 1, 2020 | Fairmont Queen Elizabeth | Montreal, Quebec Learn More Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the first in-vitro diagnostic POC and home testing device to measure the inflammatory marker,
Continue Reading

IBDoc Key Literature List

IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay!   View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading

100 BÜHLMANN Calprotectin Publications

BÜHLMANN launched its first fecal calprotectin assay over 10 years ago and since then has developed into THE CALPROTECTIN COMPANY with the highest quality standards. The offerings include the FDA 510(k) cleared BÜHLMANN fCAL® ELISA, the FDA 510(k) cleared automated BÜHLMANN fCAL® turbo (in combination with CALEX® Cap fecal extraction device) for testing on most
Continue Reading

IBDoc® Talk #2

IBDoc® IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. Based on BÜHLMANN’s long-lasting experience with calprotectin assays, IBDoc® provides IBD patients a convenient method for self-testing. CALEX® Valve has been developed for simple and easy-to-handle stool extraction with a valve designed to allow the precise application
Continue Reading

BUHLMANN Debriefing- EuroMedLab 2019

BÜHLMANN Educational Workshop at EuroMedLab 2019 The BÜHLMANN Educational Workshop at EuroMedLab 2019, focused on optimizing workflow for fecal calprotectin testing was a great success.  This workshop offered insightful presentations from three laboratories discussing the process of stool sample pre-analytics and how they worked to find a solution to cope with continuously increasing test numbers.
Continue Reading

Visit BUHLMANN at Meeting of the Minds 2019

Meeting of the Minds 2019 BUHLMANN Diagnostics Corp Stop by our Booth! Nov 15-16, 2019 | Ritz Carlton Hotel | Toronto, ON Event Info: https://crohnsandcolitis.ca/meetingoftheminds Visit our booth to get an update on our IBDoc® Calprotectin Home Test: IBDoc®, the in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal calprotectin Learn More Click & Contact Meeting of the Minds
Continue Reading

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain.  P1750.  Read Citation BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is Not Available for Sale in the US.
Continue Reading

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading